SE0201726D0 - New method and composition - Google Patents

New method and composition

Info

Publication number
SE0201726D0
SE0201726D0 SE0201726A SE0201726A SE0201726D0 SE 0201726 D0 SE0201726 D0 SE 0201726D0 SE 0201726 A SE0201726 A SE 0201726A SE 0201726 A SE0201726 A SE 0201726A SE 0201726 D0 SE0201726 D0 SE 0201726D0
Authority
SE
Sweden
Prior art keywords
allogeneic
antigen
cellular
pulsing
apc
Prior art date
Application number
SE0201726A
Other languages
Swedish (sv)
Other versions
SE0201726L (en
SE523515C2 (en
Inventor
Alex Karlsson-Parra
Annacarin Wallgren
Bengt Andersson
Original Assignee
Alex Karlsson Parra
Annacarin Wallgren
Bengt Andersson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alex Karlsson Parra, Annacarin Wallgren, Bengt Andersson filed Critical Alex Karlsson Parra
Priority to SE0201726A priority Critical patent/SE523515C2/en
Publication of SE0201726D0 publication Critical patent/SE0201726D0/en
Priority to ES03730977T priority patent/ES2369077T3/en
Priority to DK03730977.0T priority patent/DK1509244T3/en
Priority to AU2003241252A priority patent/AU2003241252A1/en
Priority to EP03730977A priority patent/EP1509244B1/en
Priority to SI200332043T priority patent/SI1509244T1/en
Priority to US10/516,915 priority patent/US20050158328A1/en
Priority to PCT/SE2003/000936 priority patent/WO2003103707A1/en
Priority to AT03730977T priority patent/ATE517633T1/en
Publication of SE0201726L publication Critical patent/SE0201726L/en
Publication of SE523515C2 publication Critical patent/SE523515C2/en
Priority to US11/603,819 priority patent/US8673296B2/en
Priority to US14/164,518 priority patent/US20140141046A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Producing (M1) a cellular allogeneic vaccine (I) based upon an allogeneic antigen presenting cells (APC) (II), involves isolating (II) from a subject, modifying (II) with an antigen using pulsing, transfection, infection or fusion, treating (II) with an agent capable of removing sialic acid on surface of (II) and optionally culturing the modified (II) a suitable medium. Producing (M1) a cellular allogeneic vaccine (I) based upon an allogeneic antigen presenting cells (APC) (II), involves: (a) isolating an (II) from a subject, preferably from a normal blood donor or a patient suffering from myeloid malignancies, or providing (II) already established and/or isolated from a myeloid leukemia cell line; (b) modifying (II) with an antigen using pulsing, transfection, infection or fusion; (c) treating (II) with an agent capable of removing sialic acid on the surface of (II) and optionally; (d) culturing the modified (II) a suitable medium. Independent claims are also included for the following: (1) a cellular allogeneic vaccine (III) obtainable by (M1); (2) a composition (IV) comprising (III) and a carrier; and (3) a frozen container comprising (IV).
SE0201726A 2002-06-06 2002-06-06 Producing cellular allogeneic vaccine based upon allogeneic antigen presenting cells, by modifying isolated antigen presenting cells with antigen, treating antigen presenting cells with agent SE523515C2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE0201726A SE523515C2 (en) 2002-06-06 2002-06-06 Producing cellular allogeneic vaccine based upon allogeneic antigen presenting cells, by modifying isolated antigen presenting cells with antigen, treating antigen presenting cells with agent
AT03730977T ATE517633T1 (en) 2002-06-06 2003-06-05 NEW METHOD AND COMPOSITION FOR PRODUCING A CELLULAR ALLOGENE VACCINE
EP03730977A EP1509244B1 (en) 2002-06-06 2003-06-05 New method and composition for producing a cellular allogeneic vaccine
DK03730977.0T DK1509244T3 (en) 2002-06-06 2003-06-05 New method and preparation for producing a cellular allogeneic vaccine
AU2003241252A AU2003241252A1 (en) 2002-06-06 2003-06-05 New method and composition for producing a cellular allogeneic vaccine
ES03730977T ES2369077T3 (en) 2002-06-06 2003-06-05 NEW PROCEDURE AND COMPOSITION TO PRODUCE A CELLULAR ALLOGENIC VACCINE.
SI200332043T SI1509244T1 (en) 2002-06-06 2003-06-05 New method and composition for producing a cellular allogeneic vaccine
US10/516,915 US20050158328A1 (en) 2002-06-06 2003-06-05 Method and composition for producing a cellular allogeneic vaccine
PCT/SE2003/000936 WO2003103707A1 (en) 2002-06-06 2003-06-05 New method and composition for producing a cellular allogeneic vaccine
US11/603,819 US8673296B2 (en) 2002-06-06 2006-11-24 Method and composition for producing a cellular allogeneic vaccine
US14/164,518 US20140141046A1 (en) 2002-06-06 2014-01-27 Method and composition for producing a cellular allogeneic vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201726A SE523515C2 (en) 2002-06-06 2002-06-06 Producing cellular allogeneic vaccine based upon allogeneic antigen presenting cells, by modifying isolated antigen presenting cells with antigen, treating antigen presenting cells with agent

Publications (3)

Publication Number Publication Date
SE0201726D0 true SE0201726D0 (en) 2002-06-06
SE0201726L SE0201726L (en) 2003-12-07
SE523515C2 SE523515C2 (en) 2004-04-27

Family

ID=20288098

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201726A SE523515C2 (en) 2002-06-06 2002-06-06 Producing cellular allogeneic vaccine based upon allogeneic antigen presenting cells, by modifying isolated antigen presenting cells with antigen, treating antigen presenting cells with agent

Country Status (1)

Country Link
SE (1) SE523515C2 (en)

Also Published As

Publication number Publication date
SE0201726L (en) 2003-12-07
SE523515C2 (en) 2004-04-27

Similar Documents

Publication Publication Date Title
Ludewig et al. Dendritic cells efficiently induce protective antiviral immunity
ES2261250T3 (en) SDUPRESSOR CELLS FOR PREVENTION AND TREATMENT OF IMMUNE ANSWERS IN TRANSPLANTS.
IL248493A0 (en) Method to increase class i presentation of exogenous antigens by human dendritic cells
WO2004096975A3 (en) Apparatus and methods for amplification of blood stem cell numbers
WO2005007799A3 (en) Methods for ex-vivo expanding stem/progenitor cells
DK1604016T3 (en) In vitro method for differentiating monocytic dendritic precursor cells into immature dendritic cells
MXPA02007137A (en) Liver tissue source.
DK1634949T3 (en) Method of generating activated T cells and antigen-incubated antigen-presenting cells
MXPA05006042A (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors.
HK1080111A1 (en) Method for growth of human conjunctival tissue equivalents for research, clinical ocular surface transplantation and tissue engineering
MXPA05006350A (en) Culture medium composition, culture method, and myoblasts obtained, and their uses.
AU757443B2 (en) New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines
BR0211491A (en) Fully mature and stable dendritic cell generation of leukapheresis products for clinical applications
AU2003241252A1 (en) New method and composition for producing a cellular allogeneic vaccine
Malone et al. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer
DK1699480T3 (en) Allogeneic therapeutic tumor agent
DE60032508D1 (en) PROCESS FOR THE REPRODUCTION OF NATURAL KILLER CELLS
DE60213852D1 (en) PREPARATION OF CELL SUSPENSIONS
Westermann et al. Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties
DK1419240T3 (en) Preparation and Use of Human CD124 and CD116 Positive Tumor Cell Lines for Preparation of Allogeneic or Semi-Allogeneic Immunotherapy
SE0201726D0 (en) New method and composition
CA2505527A1 (en) Method for suppressing immune system response to transplanted tissue or cells
Chen et al. Interleukin-10-induced T cell unresponsiveness can be reversed by dendritic cell stimulation
WO2002036748A3 (en) Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
O'Connell et al. Type‐1 polarized nature of mouse liver CD8α–and CD8α+ dendritic cells: tissue‐dependent differences offset CD8α‐related dendritic cell heterogeneity

Legal Events

Date Code Title Description
NUG Patent has lapsed